RenalGuard Solutions markets the RenalGuard platform and develops medical technologies for the cardiac and vascular markets. The company has launched Reprieve Cardiovascular, led by CEO Jim Dillon, to advance Guided Diuretic Therapy for patients with acute decompensated heart failure (ADHF). Reprieve's Guided Diuretic Therapy is intended to enable precise and predictable management of fluid levels in fluid-overloaded heart failure patients and to increase diuretic efficiency. The therapy is described as having potential to speed decongestion while protecting core organ function, shorten hospital stays, reduce readmissions, and improve symptoms such as shortness of breath, ascites, and swelling. Financially, RenalGuard completed a $7M financing announced in September 2018. The round was led by Abiomed with participation from existing investors. RenalGuard Solutions develops the RenalGuard system, designed to protect patients from acute kidney injury (AKI) including contrast-induced AKI by measuring urine output and automatically infusing hydration fluid. The company reports investigator-sponsored studies in Europe that demonstrated RenalGuard’s effectiveness at preventing CI-AKI in at-risk patients. RenalGuard is CE-marked and is sold in Europe and certain countries worldwide via a network of distributors. RenalGuard Solutions is led by Chairman Ethan Benovitz and is conducting the CIN-RG pivotal study in the United States to support a planned Premarket Approval filing with the U.S. Food and Drug Administration. The company plans to use new funding to complete its ongoing pivotal trial by year-end to support U.S. marketing approval in 2018, extend marketing and sales activities in Europe and other regions, and expand R&D into additional clinical indications. The device and ongoing trial position the company for regulatory progress and broader commercial expansion where the technology is available.

Total raised

$22M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2018